These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
381 related items for PubMed ID: 19231980
1. Raltegravir: the first HIV type 1 integrase inhibitor. Hicks C, Gulick RM. Clin Infect Dis; 2009 Apr 01; 48(7):931-9. PubMed ID: 19231980 [Abstract] [Full Text] [Related]
2. Raltegravir: the first HIV integrase inhibitor. Cocohoba J, Dong BJ. Clin Ther; 2008 Oct 01; 30(10):1747-65. PubMed ID: 19014832 [Abstract] [Full Text] [Related]
3. Integrase inhibitors in the treatment of HIV-1 infection. Powderly WG. J Antimicrob Chemother; 2010 Dec 01; 65(12):2485-8. PubMed ID: 20852268 [Abstract] [Full Text] [Related]
4. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV. Prescrire Int; 2008 Aug 01; 17(96):135-7. PubMed ID: 19480091 [Abstract] [Full Text] [Related]
5. Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium. Nguyen BY, Isaacs RD, Teppler H, Leavitt RY, Sklar P, Iwamoto M, Wenning LA, Miller MD, Chen J, Kemp R, Xu W, Fromtling RA, Vacca JP, Young SD, Rowley M, Lower MW, Gottesdiener KM, Hazuda DJ. Ann N Y Acad Sci; 2011 Mar 01; 1222():83-9. PubMed ID: 21434946 [Abstract] [Full Text] [Related]
6. Novel integrase inhibitors for HIV. Prada N, Markowitz M. Expert Opin Investig Drugs; 2010 Sep 01; 19(9):1087-98. PubMed ID: 20707594 [Abstract] [Full Text] [Related]
7. Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption. Canducci F, Barda B, Ceresola E, Spagnuolo V, Sampaolo M, Boeri E, Nozza S, Cossarin F, Galli A, Gianotti N, Castagna A, Lazzarin A, Clementi M. Clin Microbiol Infect; 2011 Jun 01; 17(6):928-34. PubMed ID: 20854427 [Abstract] [Full Text] [Related]
9. Emergence of raltegravir-resistant HIV-1 in the central nervous system. Watanabe K, Honda M, Watanabe T, Tsukada K, Teruya K, Kikuchi Y, Oka S, Gatanaga H. Int J STD AIDS; 2010 Dec 01; 21(12):840-1. PubMed ID: 21297097 [Abstract] [Full Text] [Related]
14. Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients. Malet I, Delelis O, Soulie C, Wirden M, Tchertanov L, Mottaz P, Peytavin G, Katlama C, Mouscadet JF, Calvez V, Marcelin AG. J Antimicrob Chemother; 2009 Apr 01; 63(4):795-804. PubMed ID: 19221102 [Abstract] [Full Text] [Related]
15. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy. Van Vaerenbergh K. Verh K Acad Geneeskd Belg; 2001 Apr 01; 63(5):447-73. PubMed ID: 11813503 [Abstract] [Full Text] [Related]
16. New therapeutic strategies for raltegravir. Garrido C, Soriano V, de Mendoza C. J Antimicrob Chemother; 2010 Feb 01; 65(2):218-23. PubMed ID: 20016017 [Abstract] [Full Text] [Related]
18. Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy. McColl DJ, Chen X. Antiviral Res; 2010 Jan 01; 85(1):101-18. PubMed ID: 19925830 [Abstract] [Full Text] [Related]
20. A new drug combination therapy for treatment-naive patients with HIV-1 infection, consisting of raltegravir, emtricitabine and tenofovir disoproxil fumarate. De Clercq E. Expert Opin Pharmacother; 2009 Dec 01; 10(17):2935-7. PubMed ID: 19929712 [Abstract] [Full Text] [Related] Page: [Next] [New Search]